Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 through 80 years (20 to 75 years in Japan)~* Written consent~* Diagnosis of adult onset Rheumatoid Arthritis (RA) of at least 3 months duration as defined by the 1987 American College of Rheumatology (ACR) classification criteria (Arnett et al, 1988)~* Treatment with methotrexate at a stable and tolerated doses~* Positive anti-cyclic citrullinated peptide (CCP) immuno-globulin G antibodies (more than \[\>\] 5 international unit per milliliter \[IU/mL\]) and/or rheumatoid factor (RF \>14 IU/mL) at screening~* Received more than or equal to (\>=) 5 milligram (mg) per week folic acid as a single or divided dose during the study.~Exclusion Criteria:~* A rheumatic autoimmune disease other than RA~* A history of, or current, inflammatory joint disease other than RA or other systemic autoimmune disorder~* Subjects at a high risk of infection~* Subjects (male and female) of reproductive potential who are not willing to use contraception from screening through the end date of the trial~* History of methotrexate or any drug-induced lung fibrosis or pneumonitis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Mavrilimumab 10 mg (Type: EXPERIMENTAL): Mavrilimumab (CAM-3001) 10 milligram (mg) injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
- Mavrilimumab 30 mg (Type: EXPERIMENTAL): Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
- Mavrilimumab 50 mg (Type: EXPERIMENTAL): Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
- Mavrilimumab 100 mg (Type: EXPERIMENTAL): Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.

Based on this trial design, predict the completion outcome and termination type (if applicable).